Ingalls & Snyder LLC Bristol Myers Squibb CO Transaction History

Ingalls & Snyder LLC

$2.56 Billion
Q3 2024

A detailed history of Ingalls & Snyder LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Ingalls & Snyder LLC holds 12,700 shares of BMY stock, worth $739,521. This represents 0.03% of its overall portfolio holdings.

Number of Shares

12,700

Previous 12,700 -0.0%

Holding current value

$739,521

Previous $527,000 24.67%

% of portfolio

0.03%

Previous 0.02%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$39.66 - $51.75 $1.25 Million - $1.63 Million	-31,505 Reduced 16.3%	161,831 $8.37 Million
Q2 2024 Jul 31, 2024	SELL	$40.25 - $52.99 $11.1 Million - $14.6 Million	-274,803 Reduced 58.7%	193,336 $8.03 Million
Q1 2024 May 13, 2024	BUY	$47.98 - $54.4 $1.73 Million - $1.96 Million	36,072 Added 8.35%	468,139 $25.4 Million
Q4 2023 Jan 29, 2024	SELL	$48.48 - $57.85 $2.52 Million - $3 Million	-51,879 Reduced 10.72%	432,067 $22.2 Million
Q3 2023 Nov 02, 2023	SELL	$57.89 - $64.73 $295,528 - $330,446	-5,105 Reduced 1.04%	483,946 $28.1 Million
Q2 2023 Jul 27, 2023	BUY	$63.71 - $70.74 $662,456 - $735,554	10,398 Added 2.17%	489,051 $31.3 Million
Q1 2023 May 09, 2023	BUY	$65.71 - $74.53 $1.12 Million - $1.27 Million	17,032 Added 3.69%	478,653 $33.2 Million
Q4 2022 Jan 31, 2023	SELL	$68.48 - $81.09 $648,779 - $768,246	-9,474 Reduced 2.01%	461,621 $33.2 Million
Q3 2022 Oct 21, 2022	SELL	$0.13 - $76.84 $230 - $136,237	-1,773 Reduced 0.37%	471,095 $33.5 Million
Q2 2022 Aug 11, 2022	SELL	$72.62 - $79.98 $219,602 - $241,859	-3,024 Reduced 0.64%	472,868 $36.4 Million
Q1 2022 May 09, 2022	BUY	$61.48 - $73.72 $149,765 - $179,581	2,436 Added 0.51%	475,892 $34.8 Million
Q4 2021 Feb 11, 2022	SELL	$53.63 - $62.52 $991,994 - $1.16 Million	-18,497 Reduced 3.76%	473,456 $29.5 Million
Q3 2021 Oct 27, 2021	SELL	$59.17 - $69.31 $672,407 - $787,638	-11,364 Reduced 2.26%	491,953 $29.1 Million
Q2 2021 Aug 03, 2021	BUY	$61.91 - $67.42 $66,243 - $72,139	1,070 Added 0.21%	503,317 $33.6 Million
Q1 2021 Apr 21, 2021	SELL	$59.34 - $66.74 $600,758 - $675,675	-10,124 Reduced 1.98%	502,247 $31.7 Million
Q4 2020 Jan 27, 2021	BUY	$57.74 - $65.43 $29.6 Million - $33.5 Million	512,371 New	512,371 $31.8 Million
Q3 2020 Oct 21, 2020	SELL	$57.43 - $63.64 $29.3 Million - $32.4 Million	-509,601 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$54.82 - $64.09 $76,090 - $88,956	1,388 Added 0.27%	509,601 $30 Million
Q1 2020 Apr 22, 2020	BUY	$46.4 - $67.43 $520,515 - $756,429	11,218 Added 2.26%	508,213 $28.3 Million
Q4 2019 Jan 15, 2020	BUY	$49.21 - $64.19 $5.03 Million - $6.56 Million	102,242 Added 25.9%	496,995 $31.9 Million
Q3 2019 Oct 16, 2019	SELL	$42.77 - $50.71 $491,170 - $582,353	-11,484 Reduced 2.83%	394,753 $20 Million
Q2 2019 Jul 11, 2019	BUY	$44.62 - $49.34 $9.19 Million - $10.2 Million	206,048 Added 102.93%	406,237 $18.4 Million
Q1 2019 Apr 11, 2019	BUY	$45.12 - $53.8 $451,019 - $537,784	9,996 Added 5.26%	200,189 $9.55 Million
Q4 2018 Jan 24, 2019	SELL	$48.76 - $63.23 $360,531 - $467,522	-7,394 Reduced 3.74%	190,193 $9.89 Million
Q3 2018 Oct 24, 2018	SELL	$55.19 - $62.25 $41,006 - $46,251	-743 Reduced 0.37%	197,587 $12.3 Million
Q2 2018 Aug 10, 2018	SELL	$50.53 - $62.98 $16,270 - $20,279	-322 Reduced 0.16%	198,330 $11 Million
Q1 2018 Apr 17, 2018	BUY	$59.92 - $68.98 $184,613 - $212,527	3,081 Added 1.58%	198,652 $12.6 Million
Q4 2017 Jan 19, 2018	BUY	$59.94 - $65.35 $13,486 - $14,703	225 Added 0.12%	195,571 $12 Million
Q3 2017 Oct 20, 2017	BUY	$55.23 - $63.74 $10.8 Million - $12.5 Million	195,346	195,346 $12.5 Million

Others Institutions Holding BMY

# of Institutions

2,533

Shares Held

1.47B

Call Options Held

31.6M

Put Options Held

35M

View Full List

About BRISTOL MYERS SQUIBB CO

Ticker BMY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 2,126,160,000
Market Cap $124B
Description
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...

More about BMY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ingalls & Snyder LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ingalls & Snyder LLC with notifications on news.

Account

Ingalls & Snyder LLC Bristol Myers Squibb CO Transaction History